1 / 26

Ethical Considerations Associated with Investigator Payments & Patient Recruitment Ginger Clasby - EVP, Business Dev

Ethical Considerations Associated with Investigator Payments & Patient Recruitment Ginger Clasby - EVP, Business Development Promedica International Costa Mesa, CA 714-799-1617 x 25 gclasby@promedica-intl.com. Popular Media Headlines What the Public Hears….

ping
Download Presentation

Ethical Considerations Associated with Investigator Payments & Patient Recruitment Ginger Clasby - EVP, Business Dev

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Ethical Considerations Associated with Investigator Payments & Patient Recruitment Ginger Clasby - EVP, Business Development Promedica International Costa Mesa, CA 714-799-1617 x 25 gclasby@promedica-intl.com

  2. Popular Media HeadlinesWhat the Public Hears… “Drug Trials Hide Conflicts for Doctors” – NY Times, 1999 “Research for Hire: A Doctor’s Drug Studies Turn into Fraud” - NY Times, 1999 “Safety Concerns Halt Oklahoma Research” – NY Times, 2000 “Probes Targeted UCI Researcher” – LA Times, 2006

  3. Background – Drug Development Climate1990’s Forward • Managed care’s strong emphasis on cost containment • Increased industry emphasis on new drug development (to preserve/increase revenues) • FDA reforms improve product review efficiencies

  4. Background - Drug Development ClimateIndustry’s Tactical Changes Med school research inefficiencies & patient enrollment timetables at odds with industry drug development timelines • Industry develops private practitioner researchers & provides significant subject enrollment incentives • Subject recruitment programs become increasingly sophisticated

  5. Background - Drug Development ClimateInteresting Statistics • Industry investment in biomedical R&D increased from 32% in 1980 to 62% in 2000* • Ave. time from IND to product approval dropped from 9.2 yr (1987 -1989) to 7.2 yr (1999-2001)** • Investigator grants paid by PhRMA member companies increased from $3.2 billion (1993) to $12.2 billion (projected 2005)** • Currently ~ 50,000 clinical trials taking place in US** Sources: *Business Week, **Thomson CenterWatch

  6. Typical Investigator Compensation Programs$$$$$$$$! • Flat fee for each subject enrolled Covers cost of exams, treatments, staff time, overhead • Bonuses paid for subjects enrolled within accelerated timeframe or above target numbers • Finder’s fees or gifts for eligible subjects • Medical writing support

  7. Median US Cost/Patient$$$$$$$$! • $9,800 Oncology trials • $9,000 CNS trials • $8,900 Anti-infective trials • $4,500 Hematology trials • $6,900 Endocrine trials • $6,500 Gastrointestinal trials Fast Track Systems: Industry Study Cost Trends, October 2003

  8. And SoIn the Rush to Enroll… • Subject disqualification criteria may be overlooked • Subjects may not be given full disclosure regarding trial objectives • Subjects may not be given full disclosure regarding associated risks • Subjects may be rushed to participate (without given time to think it over)

  9. Investigator ManagementFDA’s Toolbox • Investigator Agreement – Form 1572 • Financial Disclosure by Clinical Investigators • FDA Bioresearch Monitoring Program – Clinical Sites, Sponsors, IRBs • Application of sanctions in association with violative behaviors BUT - FDA does not have authority to review financial agreements

  10. Investigator ManagementSponsor’s Toolbox • Appropriate financial agreements • Formal investigator training programs • Study monitoring activities • Internal auditing program • Investigator termination from study

  11. Investigator ManagementInvestigator Agreement – FDA Form 1572 • Commits to conduct study in accordance with protocol, FDA regulations & IRB conditions • Commits to ensure informed consent requirements are met for all subjects (including controls) • Commits to ensure that IRB reviews & approves study initially & on a continuing basis Disregard to terms of agreement may be considered a criminal offense

  12. Investigator ManagementFDA Investigator Financial Disclosure • Applies to FDA-directed marketing applications only • No financial arrangements where study outcome may affect investigator compensation • Investigator has no proprietary interest in tested product • Investigator has no significant equity interest in company • Investigator has not received significant payments of other sorts

  13. Investigator ManagementFDA Bioresearch Monitoring Program • Comprehensive program of on-site inspections & data audits to monitor all aspects of conduct & reporting of FDA-regulated research • Inspections typically include clinical investigators, IRBs, sponsor &/or CRO

  14. Investigator ManagementFDA Sanctions • Exclusion of questionable quality or integrity data • Restriction of parties corrupting process through misconduct of malfeasance • Notification to affected parties to implement corrective action

  15. Investigator ManagementInvestigator Training Programs by Sponsor • Provide detailed training on protocol implementation, study-related documentation & GCP • Provide periodic training throughout study based on protocol or procedural amendments • Training should be documented

  16. Investigator ManagementStudy Monitoring Activities by Sponsor • Perform study initiation visits • Perform interim study visits at appropriate intervals • Perform appropriate study data review to ID protocol deviations, data inconsistencies, unreported safety events • Review IRB submissions & responses Get technical Fill in the blanks Don’t be intimidated Address nonconformities appropriately

  17. Investigator ManagementInternal Audits by Sponsor • Perform interim site audits by trained auditors uninvolved in study Be suspicious Expect fraud

  18. Investigator ManagementInvestigator Termination by Sponsor • Terminate shipment of investigational product • Terminate investigator participation in study • Report investigator to FDA

  19. The Role of the IRB • Responsible for subject rights & welfare May insist on documentation of GCP training • Reviews/approves study protocol & consent documents • Reviews/approves most subject recruitment materials • Reviews periodic study progress reports • Reviews serious adverse event reports

  20. 21 CFR 50.25Consent Document Must Include • Study involves “research”; explains research purpose • Known risks/benefits • Alternative treatments or procedures • Extent to which confidentiality will be maintained • Compensation & medical tx available in event of injury or illness • Contact(s) to discuss study/subject rights • Participation is voluntary

  21. 21 CFR 50.25Add’l Consent Document Language • Tx may involve unforeseeable risks • Anticipated circumstances when participation may be terminated w/o regard to consent • Additional costs to subject for participation • Consequences associated with withdrawal of consent • Commitment to provide info on significant new findings during study that may affect willingness to participate • Approximate # of subjects involved

  22. Subject Recruitment ProgramsWANTED – Study Subjects NOW! • Study websites • Call centers • Professional referrals • Community outreach • In-office awareness materials • Direct to patient media advertising – newspaper, radio, TV, bulletin boards, posters, flyers, etc. • Financial compensation

  23. Subject Recruitment ProgramsPrint Recruitment Advertising Should Include • Name & address of investigator or research facility • Condition under study or purpose of research • Summary of criteria used to determine study eligibility • Brief list of participation benefits (including cash) • Time or other commitment required of participants • Location of research & who to contact for further information

  24. Subject Recruitment ProgramsResearch Subject Payments • Payment amount & schedule must be approved by IRB • Payment amount should be reasonable – not coercive • Payment schedule should accrue - not contingent on study completion

  25. IRB Review of Subject Recruitment MaterialsProhibited Practices • Coercive language • “New treatment” • “Free medical treatment” • “Make $100!” • Stated or implied certainty of favorable outcome • Claims of safety or effectiveness • Claims of equivalence/superiority to other products

  26. Integrity In Corporate PracticesWhat Industry Can Do • Be thoughtful about patient eligibility criteria • Be realistic with respect to enrollment timetable • Provide appropriate investigator training & oversight • Follow-up promptly & appropriately on complaints

More Related